Report
Martial Descoutures

Moderna : A reassuring message

>Pending full publication of phase I data - We organised a conference call with Moderna’s management yesterday. Ahead of the company’s Science day scheduled for 2 June, CEO Stéphane Bancel went into detail about the intermediate clinical results of its phase I trial evaluating MRNA-1273, its candidate vaccine for COVID-19. In short, these intermediate results showed an immune response (immunogenicity) and the capacity to synthesise neutralising antibodies. In ter...
Underlying
Moderna Inc.

Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch